Paul Richardson, MD - After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology and stem cell transplant from 1994 onwards at Dana-Farber Cancer Institute (DFCI), Dr Richardson joined the Jerome Lipper Myeloma Center in 1999, was appointed Clinical Director in 2001, and led the study and development of several pivotal novel drugs including thalidomide, lenalidomide, bortezomib, pomalidomide, panobinostat, daratumumab, elotuzumab, and ixazomib. In this context, Dr Richardson was appointed the inaugural RJ Corman Professor of Medicine at Harvard Medical School in 2012, and then became Clinical Program Leader and Director of Clinical Research in 2014.
Primary Specialty
Oncologist
GenderMale
EducationUniversity of London, St. Bartholomew's Medical College
CertificationInternal Medicine, Internal Medicine, Internal Medicine
ServicesDana-Farber Cancer Institute provides oncology services in Boston, MA. Oncology includes the diagnosis and treatment of breast cancer, skin cancer, prostate cancer, and many other forms of cancer.
Contact Paul Richardson, MD at (877) 442-3324 for specific information about cancer treatment in Boston, MA.